Delhi High Court Seeks Response on Delay in Ranitidine Safety Review
The Delhi High Court has issued notices to the Centre and drug regulatory bodies, including CDSCO, DTAB, and ICMR, seeking responses on a petition demanding a timely completion of the safety review of Ranitidine. The petition highlights unresolved concerns since 2019 about NDMA, a probable carcinogen found in the drug. While other countries acted in 2020, India's regulators have yet to release a final decision. The court noted delays despite deadlines set for report submissions, with the matter still under review as of October 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (39/100). Lens Score 65/100.
Outlets measured: hindustantimes, hindustantimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (28–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
hindustantimes broke this story on 4 Nov, 10:41 am. Other outlets followed.
- 1